CMX157, a novel lipid acyclic nucleoside phosphonate, “is up to 60-fold more active against HBV and more than 200-fold more active against all major
HIV subtypes in vitro” compared with
Viread (tenofovir disoproxil fumarate [DF], Gilead Sciences), according to the release. In a phase 1 clinical trial among healthy volunteers, CMX157 showed a favorable safety, tolerability and drug distribution profile.